Читать книгу The Peripheral T-Cell Lymphomas - Группа авторов - Страница 80

Chiarle et al. reported the first transgenic mouse in which NPM1‐ALK expression was driven by the Cd4 promoter developed thymic lymphomas and plasmacytomas [23]. They further demonstrated the pathogenic roles of STAT3 in ALCL with NPM1‐ALK expression using the mice [24]. Subsequently, Turner et al. generated mice transgenic for a human NPM1‐ALK fusion gene regulated by the hematopoietic cell‐specific Vav promoter [25]. These mice exhibited development of B‐cell lymphomas and plasmacytomas. Similarly, transgenic mice expressing the NPM1‐ALK transgene regulated by the T cell‐specific Cd2 promoter also developed B‐lymphoid malignancies with variable histological features [26].